window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Hematology

  • Clinical Development,Clinical studies,Hematology,Regulatory Affairs,Research & Development

    MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD

    MaaT Pharma has published retrospective real-world data from its CHRONOS [...]

    April 10, 2026
  • Cell & Gene Therapy,Hematology,Manufacturing,Partnerships & Funding,Rare Diseases,Research & Development,Technology and platforms

    UMass Chan, Caring Cross and Trenchant BioSystems form sickle cell gene therapy manufacturing alliance

    UMass Chan Medical School, Caring Cross and Trenchant BioSystems have [...]

    March 31, 2026
  • Hematology,Oncology,Research & Development

    Inflammation linked to bone loss in aggressive childhood leukemia

    Researchers identify an IL-1β-driven inflammatory loop behind bone damage and [...]

    March 27, 2026
  • Biotech,Clinical Trials,FDA,Hematology,Rare Diseases,Regulatory Affairs

    Hemab Therapeutics wins FDA breakthrough therapy status for sutacimig in Glanzmann thrombasthenia

      The FDA has granted breakthrough therapy designation to Hemab [...]

    March 5, 2026
  • Biotech,Clinical Development,Clinical Trials,Hematology,Immunology,Pharmaceuticals and therapeutics

    Affibody licensee Rallybio reports Phase 1 data showing sustained complement inhibition with RLYB116

    Affibody has reported positive Phase 1 data from its licensee [...]

    February 19, 2026
  • Diagnostics,Hematology,Oncology,Real world evidence

    Quest Diagnostics launches flow cytometry MRD blood test for myeloma to support ultrasensitive monitoring

    Quest Diagnostics has introduced a new blood-based test for measurable [...]

    February 4, 2026
  • Biotech,Clinical Development,Drug Development,European biotech,Hematology,Research & Development,Respiratory

    Cereno Scientific publishes first peer-reviewed data on HDAC inhibitor CS014 showing antithrombotic effects without bleeding risk

    Cereno Scientific has published the first peer-reviewed paper describing its [...]

    January 16, 2026
  • Biologics & Biosimilars,Hematology,Pharmaceuticals and therapeutics

    Grifols fibrinogen concentrate FESILTY approved in the US for acute bleeding in congenital fibrinogen deficiency

    Grifols has received US Food and Drug Administration (FDA) approval [...]

    January 2, 2026
  • Diagnostics,Hematology,Medical devices,Partnerships & Funding

    Appleton blood centre adopts Reveos automation to boost platelet supply

    The Community Blood Center (CBC) in Appleton, Wisconsin has adopted [...]

    December 12, 2025
  • Cell & Gene Therapy,Clinical studies,Clinical Trials,Events and Conferences,Hematology,Oncology,Pharmaceuticals and therapeutics

    CytoAgents to present new CTO1681 clinical safety data at ASH annual meeting

    CytoAgents will present new clinical safety data for CTO1681 at [...]

    December 3, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top